IL18 and breast carcinoma: The increase in Il-18 expression seen at both the level of mRNA and protein in tumors treated with MSU-42011, but not bexarotene, suggests that this RXR agonist promotes a pro-inflammatory tumor microenvironment, which can be harnessed for breast cancer treatment.